Published in J Cardiovasc Electrophysiol on January 01, 2005
Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation (2007) 4.37
PQ segment depression in patients with short QT syndrome: a novel marker for diagnosing short QT syndrome? Heart Rhythm (2014) 2.03
Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm (2009) 1.51
Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol (2010) 1.21
Short QT syndrome. CMAJ (2005) 1.17
Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol (2005) 1.11
Adrenergic regulation of a key cardiac potassium channel can contribute to atrial fibrillation: evidence from an I Ks transgenic mouse. J Physiol (2007) 1.10
Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther (2008) 1.09
Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. Eur J Hum Genet (2007) 1.08
Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol (2008) 1.07
Potassium-channel mutations and cardiac arrhythmias--diagnosis and therapy. Nat Rev Cardiol (2012) 1.04
Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine. Cardiovasc Res (2011) 0.93
Short QT syndrome review. J Interv Card Electrophysiol (2008) 0.90
The short QT syndrome. J Interv Card Electrophysiol (2011) 0.88
Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome. J Mol Cell Cardiol (2009) 0.88
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol (2007) 0.86
The hERG K(+) channel S4 domain L532P mutation: characterization at 37°C. Biochim Biophys Acta (2011) 0.85
hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine. J Am Heart Assoc (2015) 0.85
Channelopathies: Brugada syndrome, long QT syndrome, short QT syndrome, and CPVT. Herz (2009) 0.84
Congenital short QT syndrome. Indian Pacing Electrophysiol J (2010) 0.83
Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants. J Mol Cell Cardiol (2014) 0.81
Short QT syndrome in infancy. Therapeutic drug monitoring of hydroquinidine in a newborn infant. Br J Clin Pharmacol (2011) 0.80
[Ion channel diseases in children]. Herzschrittmacherther Elektrophysiol (2014) 0.79
Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel. PLoS One (2012) 0.78
[Primary electrical heart disease in adulthood--electrophysiological findings and therapy]. Herzschrittmacherther Elektrophysiol (2005) 0.77
Short QT syndrome in a pediatric patient. Pediatr Cardiol (2009) 0.76
[Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies]. Herzschrittmacherther Elektrophysiol (2015) 0.76
Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome? J Mol Cell Cardiol (2006) 0.75
Short QT Syndrome - Review of Diagnosis and Treatment. Arrhythm Electrophysiol Rev (2014) 0.75
Short QT syndrome in a boy diagnosed on screening for heart disease. Pediatr Int (2014) 0.75
The Pharmacogenomics of a Mutation 'Hotspot' for the Short QT Syndrome. JACC Clin Electrophysiol (2017) 0.75
Sudden cardiac death in the young: how can disease recognition and prevention in family members be improved? Herzschrittmacherther Elektrophysiol (2012) 0.75
[Short QT syndrome]. Herzschrittmacherther Elektrophysiol (2012) 0.75
Short QT Syndrome: a familial cause of sudden death. Circulation (2003) 4.23
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Idiopathic short QT interval: a new clinical syndrome? Cardiology (2000) 2.85
Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation (2004) 2.82
A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res (2003) 1.89
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Autonomic nervous system influences on QT interval in normal subjects. J Am Coll Cardiol (2002) 1.53
K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J Pharmacol Exp Ther (1994) 1.50
Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res (1991) 1.34
Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res (2000) 1.19
Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther (2001) 1.03
Sensitivity of the slow component of the delayed rectifier potassium current (IKs) to potassium channel blockers: implications for clinical reverse use-dependent effects. J Biomed Sci (1999) 0.91
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation (2005) 8.76
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation (2007) 4.37
Short QT Syndrome: a familial cause of sudden death. Circulation (2003) 4.23
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol (2012) 3.18
Natural history of Brugada syndrome: insights for risk stratification and management. Circulation (2002) 3.10
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation (2004) 2.81
Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm (2010) 2.79
Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation (2004) 2.77
Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation (2003) 2.74
Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J (2006) 2.59
The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol (2010) 2.56
Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation (2003) 2.56
Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet (2002) 2.49
Brugada syndrome: report of the second consensus conference. Heart Rhythm (2005) 2.48
Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol (2003) 2.44
Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm (2007) 2.44
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol (2008) 2.42
Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol (2005) 2.39
Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med (2008) 2.38
Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials. EuroIntervention (2014) 2.30
Right ventricular involvement in Takotsubo cardiomyopathy. Eur Heart J (2006) 2.28
De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res (2005) 2.27
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm (2011) 2.26
Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol (2012) 2.26
Fever-induced Brugada pattern: how common is it and what does it mean? Heart Rhythm (2013) 2.25
Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat (2003) 2.24
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol (2010) 2.23
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol (2004) 2.23
Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation (2002) 2.23
Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation (2005) 2.20
Coronary computed tomographic angiography for detection of coronary artery disease in patients presenting to the emergency department with chest pain: a meta-analysis of randomized clinical trials. Eur Heart J Cardiovasc Imaging (2012) 2.19
The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell (2005) 2.19
Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation (2011) 2.17
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol (2003) 2.14
Effect of opening a new catheterization laboratory on 30-day and 2-year survival rates in myocardial infarction patients. Rev Esp Cardiol (2011) 2.14
Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol (2003) 2.12
Familial pseudo-Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol (2006) 2.11
Remodelling of the right ventricle after early pulmonary valve replacement in children with repaired tetralogy of Fallot: assessment by cardiovascular magnetic resonance. Eur Heart J (2005) 2.10
Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm (2004) 2.07
Intubation depth markings allow an improved positioning of endotracheal tubes in children. Can J Anaesth (2005) 2.06
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03
A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J (2006) 2.01
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm (2011) 2.01
A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res (2008) 2.01
Is arterial pulse contour analysis using Nexfin a new option in the noninvasive measurement of cardiac output?--A pilot study. J Cardiothorac Vasc Anesth (2012) 2.00
Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncol Res Treat (2014) 1.98
Unresolved issues in transcatheter atrial fibrillation ablation: silent cerebrovascular ischemias. J Cardiovasc Electrophysiol (2012) 1.98
Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci (2003) 1.97
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation (2005) 1.94